Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
This study focused on comparing neoadjuvant immunotherapy using immune checkpoint inhibitors (ICIs) with surgery and/or chemotherapy in patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) resectable gastroesophageal adenocarcinoma...
Anti-EGFR (epidermal growth factor receptor) therapies are a cornerstone of treatment for metastatic colorectal cancer (mCRC), particularly in patients with RAS/BRAF wild-type tumors. EGFR is a transmembrane receptor...
Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate of only 13% due to its aggressive nature and high recurrence rates even after surgery....
Hepatocellular carcinoma (HCC) and liver-related events (such as decompensation and cirrhosis progression) are significant complications in individuals with hepatitis D virus (HDV) infection. HDV infection is known to...
Mitogen-Activated Protein Kinase (MAPK) signaling is an essential pathway regulating cell processes like proliferation, differentiation, apoptosis, inflammation, and stress responses. Dysregulation of this pathway is a key factor...
Vascular Endothelial Growth Factor (VEGF) is a key protein involved in the development and progression of liver tumors, especially hepatocellular carcinoma (HCC), which is the most common type...
KRASG12D mutation plays a pivotal role in pancreatic tumorigenesis, particularly in the context of the adult pancreas, which is characterized by unique biological features and challenges. Below is...
High fecal immunochemical test (FIT) results in colorectal cancer (CRC) patients are strongly associated with significantly worse 1-year mortality outcomes, according to the study. Below is a detailed...
The combination of encorafenib, cetuximab, and mFOLFOX6 has been studied as a first-line treatment for patients with BRAF V600E–mutated metastatic colorectal cancer (mCRC), a particularly aggressive cancer subtype...
The international, randomized phase 3 clinical trial compared trastuzumab deruxtecan with ramucirumab plus paclitaxel as second-line treatment options for patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.